Title: Identification of CGT1263, a Potent KRAS Inhibitor with Selectivity for Mutant KRAS over HRAS and NRAS Session Date and Time: Poster Session B, Friday, October 24, 2025 – 12:30 p.m. – 4:00 p.m.

Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) is a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses and ...

In the ovarian cancer cohort, the median time to response was 1.3 months and median duration of response was 8.0 months. Post the September 4, 2025 data cutoff date, four uPRs were confirmed and one ...

Strong safety, tolerability and efficacy data in a biomarker-defined advanced UC population supports further development of FX-909 in the ongoing Part B of the Phase 1 study On-demand webinar ...

Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced it will be featured in two ...

The first CNT100 SEMI reactor was shipped to FST in September 2024. In July 2025, Canatu announced that the reactor and associated post-processing equipment had passed the customer approval (Site ...

Remix Therapeutics Announces Positive Preliminary Data from Phase 1 Study of REM-422 in Patients with Adenoid Cystic Carcinoma at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets ...

Margus and Quake join 23andMe Research Institute founder, Anne Wojcicki; Professor in Residence of Pediatrics and Epidemiology, and endowed chair in Pediatric Research at UCSF, Dr. Janet Wojcicki, PhD ...

About HealthLynked Corp. HealthLynked Corp. is transforming healthcare by connecting patients and providers through a secure, cloud-based network. The company's platform consolidates medical records, ...

At the closing of the transaction, SciSparc received 63,300,000 common shares of Neurothera, 4,000,000 common share purchase warrants (the “Payment Warrants”) and up to 48,000,000 contingent rights of ...

Anti-tumor activity was observed in heavily pretreated mCRPC patients across all dose cohorts; in 22 patients who completed at least 2 cycles of therapy, 59% achieved PSA50 response and 32% achieved ...

Ted Karkus, CEO and Chairman of the Board of Directors, will be presenting at 11AM ET on October 30 th. One-on-one investor meetings will be held throughout the day. Interested investors can register ...